Protagonist Therapeutics, Inc. (PTGX)

盈利方式

All revenue comes from two collaboration partners, not from selling medicines. Protagonist receives non-refundable upfront payments, development and regulatory milestone payments, and reimbursement for development work it performs, and it will receive royalties and sales milestones if the partnered drugs are approved and sold. Under the Janssen agreement it has already earned $337.5 million in milestones, is eligible for up to $630.0 million more, and would receive upward-tiering royalties of 6% to 10% on worldwide Icotyde sales. Under the Takeda agreement it received a $300.0 million upfront in April 2024 and a $25.0 million milestone in September 2025; it shares US profits and losses on rusfertide 50/50 with Takeda and takes 10% to 17% tiered royalties on ex-US sales, but it holds a right to opt out of the US profit share — which the filing says it expects to exercise in the second quarter of 2026 — in exchange for royalties of 14% to 29% on worldwide sales, up to $400.0 million in opt-out payments and up to $975.0 million of milestones in total. The practical consequence is that revenue is lumpy and event-driven: $60.0 million in 2023, $434.4 million in 2024, $46.0 million in 2025.

The company's advantage rests on intangibles: a peptide discovery platform, patents and trade secrets, and regulatory designations. Rusfertide carries Orphan Drug status, Fast Track and, since August 2025, Breakthrough Therapy designation, and orphan status can bring extended market exclusivity. That the platform produced two first-in-class molecules that two of the largest pharmaceutical companies were willing to license — and to pay $300.0 million upfront for, in Takeda's case — is external evidence that the science is hard to copy. The advantage is narrow rather than wide because nothing is yet approved: there are no marketed products, no commercial organisation, no manufacturing plants of its own, and the economics depend on partners the company does not control.

The underlying end demand is medical, not economic: polycythemia vera is a chronic rare blood disorder whose patients need continuous hematocrit control — the filing notes that about 78% of treated patients do not maintain hematocrit below 45% despite current therapies — and moderate-to-severe plaque psoriasis is likewise a chronic condition. Neither waits for a business cycle. But this does not make Protagonist's own reported revenue steady: it is milestone-driven and extremely lumpy, swinging from $60.0 million in 2023 to $434.4 million in 2024 to $46.0 million in 2025, and it turns on regulatory dates and partner decisions rather than on demand. Until a partnered drug is launched and generating royalties, the numbers a reader sees each year reflect contract events, not patient volumes.

主要风险

• Everything depends on a handful of unapproved candidates — The company states it is heavily dependent on the success of its product candidates in clinical development, that it has no products approved for commercial sale and may never develop a marketable product, and that a substantial portion of its spending over the next few years will go to these candidates. If Icotyde or rusfertide fail to obtain approval or are not successfully commercialised, the business would be adversely affected.
• The partners, not Protagonist, decide the fate of the lead drugs — A dedicated risk factor warns that if Janssen does not elect to continue developing or successfully commercialise Icotyde, or if Takeda does not elect to commercialise rusfertide, the business and its prospects would be adversely affected. For drugs licensed to third parties the company says it generally will not have discretion over marketing decisions, and if a collaborator fails its obligations or terminates the agreement, future milestone and royalty payments may never arrive.
• Regulatory approval is long, costly and uncertain — The filing states that the approval processes of the FDA and comparable foreign authorities are lengthy and time consuming, and that if the company or its collaborators are ultimately unable to obtain approval for the candidates, the business will be substantially harmed. Trials may fail to demonstrate safety and efficacy sufficient to support approval, and any delay would be expected to hurt the business and the share price.
• Cumulative losses and future capital needs — The company discloses a cumulative net loss since inception and warns it may incur significant losses in the future; the accumulated deficit through 31 December 2025 was about $470 million and the 2025 net loss was $130.1 million. It also flags that it has no approved products and no historical commercial revenue, which makes its future prospects and financial results difficult to assess.
• Reliance on third parties for trials and manufacturing — The company does not own or operate any manufacturing facilities and has no plans to build clinical or commercial scale capacity; it relies on contract manufacturers in the United States, Europe and Asia for drug substance and drug product, and on those manufacturers to source raw materials from third-party suppliers. It likewise relies on third parties to conduct its pre-clinical studies and clinical trials, and is exposed to their performance and business risks.
• Competition from larger and better-funded rivals — The company states that it faces significant competition from other biotechnology and pharmaceutical companies and that its operating results will suffer if it or its collaborators fail to compete effectively. Its own obesity disclosure compares PN-477 with Eli Lilly's retatrutide and PN-458 with tirzepatide, both from a far larger competitor.
• Intellectual property may not hold — The company warns that if it is unable to obtain or protect the intellectual property rights related to its candidates and technologies it may not be able to compete effectively. It relies on a combination of patents, trade secrets and confidentiality agreements, and specifically on trade secrets to protect parts of its peptide technology platform — protection that is inherently harder to enforce than a patent.
• Pricing pressure and healthcare legislation — The company notes that the healthcare system is under significant financial pressure to reduce costs, which could lower payment and reimbursement rates for drugs, and cites measures such as the Inflation Reduction Act of 2022 and a May 2025 executive order directing agencies to communicate most-favored-nation price targets to manufacturers. Because its economics are royalties on partners' net sales, lower realised prices flow straight through to its own revenue.

主要客户占营收的100%

The company states plainly that its customers consist of its two collaboration partners, JNJ and Takeda. For the year ended 31 December 2025 Takeda accounted for 100% of revenues; for 2024 Takeda and JNJ accounted for 62% and 38% respectively; for 2023 JNJ accounted for 100%. All revenue in each of the three years was generated in the United States. Concentration is therefore total by construction — there are only two customers, and in any given year one of them can be the whole of it.